Lineage Cell Therapeutics Appoints New Auditor
Ticker: LCTX · Form: 8-K · Filed: Jun 9, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
Related Tickers: LCTX
TL;DR
Lineage Cell Therapeutics swapped auditors to PricewaterhouseCoopers LLP, effective June 3, 2025.
AI Summary
Lineage Cell Therapeutics, Inc. announced on June 3, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm, replacing BDO USA, LLP. This change is effective immediately.
Why It Matters
A change in auditor can signal a shift in financial scrutiny or internal controls, potentially impacting investor confidence and future financial reporting.
Risk Assessment
Risk Level: low — This filing reports a routine administrative change in the company's auditor and does not involve significant financial or operational events.
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — New independent registered public accounting firm
- BDO USA, LLP (company) — Former independent registered public accounting firm
- June 03, 2025 (date) — Effective date of auditor change
FAQ
Who is Lineage Cell Therapeutics, Inc.'s new independent registered public accounting firm?
Lineage Cell Therapeutics, Inc. has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm.
Who was Lineage Cell Therapeutics, Inc.'s previous independent registered public accounting firm?
Lineage Cell Therapeutics, Inc.'s previous independent registered public accounting firm was BDO USA, LLP.
When was the change in certifying accountant effective?
The change in certifying accountant was effective as of June 03, 2025.
Did the company have any disagreements with its former accountant?
The filing does not mention any disagreements with the former accountant, BDO USA, LLP.
What is the company's principal executive office address?
The company's principal executive office is located at 2173 Salk Avenue, Suite 200, Carlsbad, California 92008.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Lineage Cell Therapeutics, Inc. (LCTX).